文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

Habitat风险评分(HRS)整合于前列腺癌放射治疗

Integration of Habitat Risk Score in Radiation Therapy for Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-10-24

本研究提出Habitat风险评分(HRS)用于前列腺癌大体肿瘤体积(GTVp)的自动勾画,并描述将HRS整合至放疗的平台。HRS引导的融合活检阳性针率显著高于参考操作,HRS6与PSA、Grade Group(GG)及Decipher显著相关(P < .0001),识别临床显著、中危和高危前列腺癌的AUC分别为0.76、0.81和0.85;放射组学模型与Decipher评分相关,联合临床变量后平均AUC在病灶层面为0.79 vs 0.87、患者层面为0.84 vs 0.94。结论认为HRS可标准化并增强肿瘤定位,实现一致且准确的GTVp勾画,提升评估客观性并已简化以便更广泛采用。

要点

  • HRS6与PSA、GG及Decipher显著相关(P < .0001)。
  • HRS6识别临床显著、中危和高危癌的AUC分别为0.76、0.81、0.85。
  • HRS引导融合活检阳性针率显著高于参考操作。

核心结论

  • HRS方法标准化并增强肿瘤定位,实现一致且准确的GTVp勾画。
  • HRS将评估客观性提升至更高水平,并已简化以便更广泛采用。

研究设计与样本

  • HRS是一种多参数磁共振成像(mpMRI)分析技术,按像素逐点赋予1至10分,评分随肿瘤侵袭性增加而升高,侵袭性以根治性前列腺切除标本的Gleason评分定义。
  • HRS以热图显示,用于指定前列腺活检靶点。
  • HRS在参加放疗推量临床试验的患者中评估,HRS引导融合活检在前瞻性入组患者中评估。
  • 以评分为6的像素定义的HRS6体积用于指导GTVp分割,并研究HRS6与肿瘤侵袭性(GG、PSA、Decipher基因组特征)的关联。
  • 采用逻辑回归模型评估HRS6区分临床显著(GG1 vs GG2+)、中危(GG1、GG2 vs GG3+)和高危(GG1、GG2、GG3 vs GG4+)癌症的能力,并研究HRS6放射组学特征建模Decipher的能力。

主要发现

  • HRS引导融合活检的阳性针率显著高于参考操作。
  • HRS6与PSA、GG及Decipher显著相关(P < .0001)。
  • HRS6识别临床显著、中危和高危癌症的AUC分别为0.76、0.81和0.85。
  • 放射组学预测模型与Decipher评分相关,联合临床变量后性能提升,病灶层面平均AUC为0.79 vs 0.87,患者层面为0.84 vs 0.94。

关键数值与推荐

  • HRS评分范围为1至10,随肿瘤侵袭性增加而升高,侵袭性以根治性前列腺切除标本的Gleason评分定义。
  • HRS6体积由评分为6的像素定义,用于指导GTVp分割。
  • HRS6识别临床显著、中危和高危癌症的AUC分别为0.76、0.81和0.85。
  • 放射组学模型联合临床变量后平均AUC在病灶层面为0.79 vs 0.87,患者层面为0.84 vs 0.94。

临床怎么用

  • HRS热图可用于指定前列腺活检靶点,HRS引导融合活检阳性针率显著高于参考操作。
  • HRS6体积可用于指导前列腺癌放疗中GTVp的分割,以标准化和增强肿瘤定位。
  • HRS6与PSA、GG及Decipher显著相关,其放射组学特征联合临床变量可提升对Decipher的建模性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adding a simultaneous focal radiation boost to prostate cancer lesions improves the effectiveness of radiation therapy (RT) without increasing toxicity. Reliable and reproducible ways for segmenting the gross prostate tumor volume (GTVp) for delivery of the boost are needed for the wider adoption of the technique. We propose Habitat Risk Score (HRS) maps for automatic contouring of the GTV and describe a platform for integration of HRS into RT of patients with prostate cancer. METHODS AND MATERIALS: HRS is a multiparametric magnetic resonance imaging (mpMRI) analysis technique that assigns on a pixel-by-pixel basis a score from 1 to 10 in increasing fashion with tumor aggressiveness as defined by the Gleason Score in radical prostatectomy specimens. HRS is displayed as a heat map and is used for assigning targets for prostate biopsy. HRS was evaluated in patients enrolled in a clinical trial for delivering RT boost. HRS-guided fusion biopsy procedure was prospectively evaluated in patients enrolled in the trial. The HRS6 volume, defined by pixels with a score of 6, was used to guide the GTVp segmentation, and the HRS6 association with tumor aggressiveness (Grade Group (GG), Prostate Specific Antigen (PSA), and genomic signatures Decipher) was investigated. Logistic regression models were used to assess the power of HRS6 in discriminating: (i) clinically significant (GG1 vs GG2+), (ii) intermediate (GG1, GG2 vs GG3+), and (iii) high-risk cancer (GG1, GG2, GG3 vs GG4+). Finally, the ability of HRS6 radiomics features to model Decipher was investigated. RESULTS: HRS-guided fusion biopsy procedure yielded a significantly higher percentage of positive cores than in the reference procedure. HRS6 showed significant correlation with PSA, GG, and Decipher (P < .0001). AUC of HRS6 for identifying clinically significant, intermediate, and high-risk cancer was 0.76, 0.81, and 0.85. The radiomics prediction models correlated with Decipher score and when combined with clinical variables improved performance, with average AUCs of 0.79 vs 0.87 (lesion-level) and 0.84 vs 0.94 (patient-level). CONCLUSIONS: The HRS approach standardizes and enhances tumor localization, thereby enabling consistent and accurate GTVp delineation. The HRS approach takes objectivity of assessment to a higher level and has been streamlined for broader adoption.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zacharaki EI, Breto AL, Algohary A, et al. Integration of Habitat Risk Score in Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 41138785. doi:10.1016/j.ijrobp.2025.09.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。